Severity and predictive factors of adverse events in pemetrexed-containing chemotherapy for non-small cell lung cancer.

about

Severity and predictive factors of adverse events in pemetrexed-containing chemotherapy for non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q47715888

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Severity and predictive factor ...... or non-small cell lung cancer.

@en

Severity and predictive factor ...... or non-small cell lung cancer.

@nl

type

Item

label

Severity and predictive factor ...... or non-small cell lung cancer.

@en

Severity and predictive factor ...... or non-small cell lung cancer.

@nl

prefLabel

Severity and predictive factor ...... or non-small cell lung cancer.

@en

Severity and predictive factor ...... or non-small cell lung cancer.

@nl

P1476

Severity and predictive factor ...... or non-small cell lung cancer.

@en

P2093

Chiho Nakashima

http://www.w3.org/2001/XMLSchema#string

Hisashi Matsunaga

http://www.w3.org/2001/XMLSchema#string

Kazutoshi Komiya

http://www.w3.org/2001/XMLSchema#string

Kentaro Iwanaga

http://www.w3.org/2001/XMLSchema#string

Norio Ureshino

http://www.w3.org/2001/XMLSchema#string

Shinya Kimura

http://www.w3.org/2001/XMLSchema#string

Tomomi Nakamura

http://www.w3.org/2001/XMLSchema#string

Tomonori Abe

http://www.w3.org/2001/XMLSchema#string

Tsuyoshi Miyahara

http://www.w3.org/2001/XMLSchema#string

P2860

Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis.

Efficacy and safety of pemetrexed in elderly cancer patients: results of an integrated analysis.

Effect of renal function on pemetrexed-induced haematotoxicity

Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.

Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma.

Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: A retrospective cohort study

P2888

s12032-017-1053-8

P304

195

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12032-017-1053-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Naoko Aragane

P577

2017-11-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29124473

http://www.w3.org/2001/XMLSchema#string